Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

in the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, RDEA684, RDEA119, RDEA806, RDEA427 and our other compounds, the timing and results of our preclinical, clinical and other studies, the sufficiency of our cash resources and our financial performance. Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs and risks related to the outcome of our business development activities, including collaboration or licensing agreements. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo: http://www.n
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... HONG KONG , August 28, 2015 ... Gero in collaboration with one of the leading academics ... Reis (current world record holder in life extension for ... new insights into biology of aging and age-related diseases, primarily, ... networks. The work has just been published as "Stability analysis ...
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
(Date:8/28/2015)... SAN FRANCISCO , August 28, 2015 ... is expected to reach USD 49.12 billion by 2020, ... 2020, according to a new report by Grand View ... an estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President ... to increase acceptance of the chiropractic field in the military. All too often VA ... Although Chiropractic was made available to the VA program over a decade ago, the ...
(Date:8/29/2015)... ... ... ProDrop Particles includes over 40 particle backdrops designed for use in ... users can shrink and stretch in the Final Cut Pro X timeline. Choose from ... scale, speed, range, and flare attributes with intuitive controls found in the top-right inspector ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number ... recently transitioned management companies to partner with Wound Care Advantage (WCA) to utilize ... center. , Transitioning wound care management providers can be a complex undertaking. ...
(Date:8/28/2015)... ... 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth ... are applying for, they are unable to pass the initial drug test and therefore ... policies in order to be able to hire long-term, skilled talent. (1) Will Wesch, ...
Breaking Medicine News(10 mins):Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... red wine drinkers have increased HDL cholesterol, commonly referred ... light on why red wine is believed to be ... cholesterol levels between 40 men who drink every now ... who are heavy drinkers. As alcohol consumption shot up, ...
... your blood clot properly.It is so important that all newborns ... The vitamin is found most commonly in leafy green vegetables ... not have bacteria established, they need supplemental vitamin K. ... 90 micrograms for women was set. Because no adverse ...
... can change easily worn muscle fibres into energy-producing muscle ... at Harvard Medical School discovered a protein in muscle ... Texas, they reveal that the protein has the power ... types of muscle fibre. Type II is the easily-fatigued ...
... be possible to increase the supply of lungs for transplant.There ... San Francisco and Nashville have been looking at the supply ... cent of lungs are rejected. That's a very high number. ... ,The researchers checked 30 pairs of lungs that had been ...
... Illinois, confirmed that a compound modelled on a substance ... Previous research has suggested that sulforaphane,// which occurs in ... does so by increasing the level of detoxifying enzymes ... toxic to cells so it may not be a ...
... to researchers from Northwestern Medical School, an injectable gel ... and neck. Head and neck squamous cell carcinoma affects ... cisplatin has been shown to be an effective therapy ... the entire body when given through an IV, it ...
Cached Medicine News:
Forceps, pointed, short jaws, suitable for epilation....
1 mm x 6 mm oval hole....
Bayonet forceps....
Gerald bayonet forceps. Insulated....
Medicine Products: